NCT00924820View on ClinicalTrials.gov

A Pilot Study of Bevacizumab for Neoplastic Meningitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Neoplastic Meningitis
Interventions
DRUG

Bevacizumab

10 mg/kg by vein over about 1 hour, every 2 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00924820 - A Pilot Study of Bevacizumab for Neoplastic Meningitis | Biotech Hunter | Biotech Hunter